The Nuts & Bolts of Due Diligence in Biopharma Partnering

In this webinar, you’ll learn the important aspects to consider during the due diligence process leading up to a successful partnership.

The topics covered in the discussion are:

The importance of IP due diligence
What big pharma expects when entering due diligence with a biopharma company
Best ways to present and stage information that is disclosed to a potential partner
The best practices for the best long-term partnerships

WATCH THE

WEBINAR REPLAY

First Name

Last Name

Business Email

Company

Job Title

I agree to the Privacy Policy

ABOUT SHAREVAULT

ShareVault’s secure document sharing solution gives organizations of all sizes in all industries the confidence to simply and securely share sensitive documents with third parties during due diligence, fundraising, board communications, and any circumstance when it is crucial that confidential information is maintained under the highest level of security and control.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.

MODERATOR AND PANELISTS:

Linda Pullan, PhD

Pullan Consulting

Linda offers biotech and pharmaceutical companies consulting in all aspects of partnering. Linda has a Ph.D. in Biochemistry, a B.S. in Chemistry, and more than twenty years of drug industry experience. Learn More

James A. McCarthy, CLP, MBA,

Corporate and Business Development, Alliance Management, CorpDev Ventures

Jim has 30 years of life sciences professional experiences with projects and deals in over 30 countries with over 80 completed agreements across a range of transactions valued in excess of $900 million. His background includes a twenty-five year career with Bristol-Myers Squibb and Eli Lilly & Company and over fifteen years in international corporate business development and licensing roles.

Natalie Mirutenko, PhD

Transaction and Due Diligence Senior Director for the Center of External Innovation at Takeda

Natalie is an accomplished biopharmaceutical Business Development professional with a strong track record of results oriented achievements in technology, company, and product licensing and acquisition. She has over 35 years of diversified biopharmaceutical experience, with scientific, financial, strategic, and business perspective.

David L. Snitman, PhD

Partner, DL Snitman Inc and Former COO, Array BioPharma

David is a partner in a biotech business development-consulting agency, DL Snitman Inc. He is a Cofounder of Array BioPharma and lead over a dozen partnering deals, providing more then $600 M in non-dilutive capital.

Patrick Gattari, JD

Partner, McDonnell Boehnen Hulbert & Berghoff

Patrick's practice focuses on patent prosecution and technology licensing, with emphasis in biotechnology, pharmaceuticals, diagnostics, and medical devices. His 20-plus years of practice has emphasized patent portfolio management and the licensing, acquisition, and sale of intellectual property. Learn More

Anne-Marie Costelloe, AFBPS

Chartered Organization Psychologist, Executive Consultant, Somerville Partners

With over 20 years of organizational development consulting with organizations, teams and individuals, Ann-Marie directly contributes to financial success by customizing solutions to help leaders increase employee engagement and contributions, align strategy and tactics, and elevate performance across the business. Learn More

William Gangi, MS, MBA

Director, Due Diligence Program Manager, Corporate Development, Shire

William currently serves as a Director, Due Diligence Program Manager within the Corporate Development department at Shire. He has 20 years of drug development, commercialization and strategic operations experience within the biopharmaceutical industry.